By Amriteshwar Mathur
Zydus Lifesciences is attempting to move up the value chain in the global pharma industry with its expanding focus on the medical technology segment. As part of the above strategy, Zydus Lifesciences has made a foray in the higher margin orthopedic products segment with an acquisition of 85.6% stake in France-based Amplitude Surgical for Euro 256.8 million (nearly Rs 2,380 crore).
This transaction is at a valuation multiple, enterprise value to sales for year ended June 2024, of nearly 3 times. The France-based company also had EBITDA margins of 25.6 % for its financial year ended 30 June 2024, according to data sourced from its website.
Acquisitions overseas by other large Indian pharma players have been done at diverse Enterprise Value (EV) to sales multiples (EV/Sales) – Sun Pharma had recently acquired US-based Checkpoint Therapeutics with a focus on solid tumor cancer for $ 355 million (nearly Rs 3,090 crore). The US-based company had sales of merely $0.04 million for nine-month ending September 2024.
Meanwhile, Dr Reddy’s in June 2024 acquired UK-based Haleon’s global portfolio in the nicotine replacement therapy segment outside the US market for about two times 12-month sales, based on annualizing data related to this product segment revenue provided by the Hyderabad-based company in its December 2024 quarter investor presentation.
For Zydus Lifesciences, the France-based acquisition comes at a time when the global orthopedic product segment is projected to grow from $ 45 billion in calendar year 2024 to $ 60 billion over the next five years. And this European pharma company is well established in the global hips and knees segment. The Ahmedabad-based company is looking to build a global medical technology business and this acquisition is a step in that direction.
The acquisition was announced on Monday and in Tuesday trade, the Zydus Lifesciences stock declined 1.2 % to Rs 889. The stock is trading not too far from its 52-week low of Rs 859 that was reached on 4 March 2025.
At the time of declaring its December 2024 quarter results, Zydus Lifesciences had highlighted its net cash position of Rs 3,091.6 crore, and to finance the French acquisition it will use a combination of internal accruals and external financing.
Expanding product portfolio
Zydus Lifesciences has been aggressively focused on expanding its product portfolio – it had recently launched ANVIMO, treatment in the prevention of cytomegalovirus infection for haematopoietic stem cell transplant (HSCT) and kidney transplant patients. In addition, it had got US FDA approval for Ketoconazole shampoo, an antifungal medication used to treat dandruff, fungal infections, and other skin conditions.
Apart from that, in early January 2025, Zydus Lifesciences had entered into an agreement with CVS Caremark for launch of medicines in the US market to improve glycemic control in adults with type- 2 diabetes. And it is also looking to expand its presence in the global medical technology business in segments like nephrology, amongst others.
Performance in the December 2024 quarter
Zydus Lifesciences consolidated revenue from operations grew nearly 17% y-o-y to Rs 5,269 crore in the December 2024 quarter helped by improved sales in the US market and consumer wellness business. Its consolidated operating profit margin fell nearly 100 basis points y-o-y to 22.9 % in the third quarter of FY25, given higher other expenses in the quarter under review.
Consolidated net profit of Zydus Lifesciences grew 33.6 % y-o-y to Rs 1,026 crore in the December 2024 quarter.
Valuations and outlook
Zydus Lifesciences trades at a P/E of nearly 20 times estimated consolidated FY 25 earnings. Other large players like Sun Pharma trade at a P/E of 34 times estimated consolidated FY25 earnings while Cipla trades at 22 times.
That’s not expensive, relatively speaking. But whether it’s attractively priced today, only time will tell.
Disclaimer:
Amriteshwar Mathur is a financial journalist with over 20 years of experience.
Disclosure: The writer holds stocks discussed in this article.
The website managers, its employee(s), and contributors/writers/authors of articles have or may have an outstanding buy or sell position or holding in the securities, options on securities or other related investments of issuers and/or companies discussed therein. The content of the articles and the interpretation of data are solely the personal views of the contributors/ writers/authors. Investors must make their own investment decisions based on their specific objectives, resources and only after consulting such independent advisors as may be necessary.